222 related articles for article (PubMed ID: 35328324)
1. Bladder Cancer Extracellular Vesicles Elicit a CD8 T Cell-Mediated Antitumor Immunity.
Ortiz-Bonilla CJ; Uccello TP; Gerber SA; Lord EM; Messing EM; Lee YF
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328324
[TBL] [Abstract][Full Text] [Related]
2. Cationized liposomal keto-mycolic acids isolated from Mycobacterium bovis bacillus Calmette-Guérin induce antitumor immunity in a syngeneic murine bladder cancer model.
Yoshino T; Miyazaki J; Kojima T; Kandori S; Shiga M; Kawahara T; Kimura T; Naka T; Kiyohara H; Watanabe M; Yamasaki S; Akaza H; Yano I; Nishiyama H
PLoS One; 2019; 14(1):e0209196. PubMed ID: 30608942
[TBL] [Abstract][Full Text] [Related]
3. Extracellular Vesicles from
Luo ZW; Xia K; Liu YW; Liu JH; Rao SS; Hu XK; Chen CY; Xu R; Wang ZX; Xie H
Int J Nanomedicine; 2021; 16():2949-2963. PubMed ID: 33907401
[TBL] [Abstract][Full Text] [Related]
4. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation.
Reyes RM; Deng Y; Zhang D; Ji N; Mukherjee N; Wheeler K; Gupta HB; Padron AS; Kancharla A; Zhang C; Garcia M; Kornepati AVR; Boyman O; Conejo-Garcia JR; Svatek RS; Curiel TJ
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33849925
[TBL] [Abstract][Full Text] [Related]
5. Effect of nitric oxide inhibition in Bacillus Calmette-Guerin bladder cancer treatment.
Langle YV; Balarino NP; Belgorosky D; Cresta Morgado PD; Sandes EO; Marino L; Bilbao ER; Zambrano M; Lodillinsky C; Eiján AM
Nitric Oxide; 2020 May; 98():50-59. PubMed ID: 32147582
[TBL] [Abstract][Full Text] [Related]
6. CD63-Mediated Antigen Delivery into Extracellular Vesicles via DNA Vaccination Results in Robust CD8
Kanuma T; Yamamoto T; Kobiyama K; Moriishi E; Masuta Y; Kusakabe T; Ozasa K; Kuroda E; Jounai N; Ishii KJ
J Immunol; 2017 Jun; 198(12):4707-4715. PubMed ID: 28507029
[TBL] [Abstract][Full Text] [Related]
7. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.
Vandeveer AJ; Fallon JK; Tighe R; Sabzevari H; Schlom J; Greiner JW
Cancer Immunol Res; 2016 May; 4(5):452-62. PubMed ID: 26921031
[TBL] [Abstract][Full Text] [Related]
8. Mutated ras p21 as a target for cancer therapy in mouse transitional cell carcinoma.
Luo Y; Chen X; Han R; Chorev M; Dewolf WC; O'Donnell MA
J Urol; 1999 Oct; 162(4):1519-26. PubMed ID: 10492248
[TBL] [Abstract][Full Text] [Related]
9. A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer.
Zhang X; Shi X; Li J; Hu Z; Zhou D; Gao J; Tan W
J Urol; 2012 Mar; 187(3):1071-9. PubMed ID: 22266013
[TBL] [Abstract][Full Text] [Related]
10. Extracellular vesicle-mediated communication between CD8
Huang Z; Liu X; Guo Q; Zhou Y; Shi L; Cai Q; Tang S; Ouyang Q; Zheng J
Front Immunol; 2024; 15():1376962. PubMed ID: 38562940
[TBL] [Abstract][Full Text] [Related]
11. Novel antitumor therapeutic strategy using CD4
Shin S; Jung I; Jung D; Kim CS; Kang SM; Ryu S; Choi SJ; Noh S; Jeong J; Lee BY; Park JK; Shin J; Cho H; Heo JI; Jeong Y; Choi SH; Lee SY; Baek MC; Yea K
Biomaterials; 2022 Oct; 289():121765. PubMed ID: 36067566
[TBL] [Abstract][Full Text] [Related]
12. Sequential administration of GM-CSF and IL-2 surface-modified MB49 cells vaccines against the metastatic bladder cancer.
Shi X; Zhang X; Li J; Guo F; Hu Z; Jing Y; Bai L; Chen S; Wan P; Wang F; Gao J; Tan W
Urol Oncol; 2013 Aug; 31(6):883-93. PubMed ID: 21924648
[TBL] [Abstract][Full Text] [Related]
13. Intravenous injection of tumor extracellular vesicles suppresses tumor growth by reducing the regulatory T cell phenotype.
Kobayashi S; Kondo N; Tomiyama T; Nakamura N; Masuda M; Matsumoto Y; Honzawa Y; Tahara T; Ikeura T; Fukui T; Okazaki K; Naganuma M
Cancer Immunol Immunother; 2023 Nov; 72(11):3651-3664. PubMed ID: 37597014
[TBL] [Abstract][Full Text] [Related]
14. Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12.
Morillon YM; Su Z; Schlom J; Greiner JW
J Immunother Cancer; 2019 Jun; 7(1):150. PubMed ID: 31186063
[TBL] [Abstract][Full Text] [Related]
15. Modulation of protective T cell immunity by complement inhibitor expression on tumor cells.
Varela JC; Imai M; Atkinson C; Ohta R; Rapisardo M; Tomlinson S
Cancer Res; 2008 Aug; 68(16):6734-42. PubMed ID: 18701498
[TBL] [Abstract][Full Text] [Related]
16. Melanoma extracellular vesicles inhibit tumor growth and metastasis by stimulating CD8 T cells.
Dan Y; Ma J; Long Y; Jiang Y; Fang L; Bai J
Mol Immunol; 2024 May; 169():78-85. PubMed ID: 38513590
[TBL] [Abstract][Full Text] [Related]
17. Non-stem bladder cancer cell-derived extracellular vesicles promote cancer stem cell survival in response to chemotherapy.
Chung WM; Molony RD; Lee YF
Stem Cell Res Ther; 2021 Oct; 12(1):533. PubMed ID: 34627375
[TBL] [Abstract][Full Text] [Related]
18. Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses.
Wang B; Zhou B; Chen J; Sun X; Yang W; Yang T; Yu H; Chen P; Chen K; Huang X; Fan X; He W; Huang J; Lin T
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38589249
[TBL] [Abstract][Full Text] [Related]
19. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
[TBL] [Abstract][Full Text] [Related]
20. Allogeneic Tumor Cell-Derived Extracellular Vesicles Stimulate CD8 T Cell Response in Colorectal Cancer.
Gates TJ; Wangmo D; Zhao X; Subramanian S
bioRxiv; 2023 Apr; ():. PubMed ID: 37131597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
